With the broad use of CD19 CAR-T cells in B-cell lymphoblastic leukemia, post-CAR-T relapse and CAR-T resistance emerge as the new clinical problems [16, 17]. Here, CD19 is linked to precursor B-cell acute lymphoblastic leukemia.